Frank­furt, London and Munich — Biosynth, a port­fo­lio company of KKR has acqui­red cela­res GmbH. The parties have agreed not to disc­lose details of the tran­sac­tion. Gibson, Dunn & Crut­cher LLP advi­sed Biosynth on this transaction.

cela­res GmbH focu­ses on the deve­lo­p­ment and produc­tion of poly­­mer-based drug carri­ers and biocon­ju­ga­ted drugs. Foun­ded in 2003, the Berlin-based company is a leader in the field of biocon­ju­ga­tion and half-life exten­sion by chemi­cal modi­fi­ca­tion, as well as the synthe­sis of specialty poly­mers for drug deli­very. cela­res offers high-quality, custo­mi­zed services, inclu­ding feasi­bi­lity studies, up-scaling and process deve­lo­p­ment, as well as the deve­lo­p­ment and vali­da­tion of the requi­red analy­ti­cal methods. In addi­tion, cela­res offers GMP produc­tion of biocon­ju­ga­tes and func­tion­a­li­zed poly­mers used as exci­pi­ents in drug formulation.

Biosynth is a criti­cal mate­ri­als supplier with global rese­arch, manu­fac­tu­ring and distri­bu­tion faci­li­ties secu­ring the supply chains of the life science indus­try. Biosynth supplies the phar­maceu­ti­cal and diagno­stic sectors. Where chemis­try meets biology, products meet services and inno­va­tion meets quality, Biosynth is “at the Edge of Inno­va­tion”. With a unique rese­arch product port­fo­lio of more than one million products and compre­hen­sive manu­fac­tu­ring services, Biosynth has exper­tise and capa­bi­li­ties in complex chemi­cals, pepti­des and key biolo­gi­cal products — all from one trus­ted part­ner. Biosynth, head­quar­te­red in Staad, Switz­er­land, is owned by KKR, Amper­sand Capi­tal Part­ners and manage­ment, among others.

Consul­tant Biosynth: Gibson Dunn
Led by London part­ner Wim De Vlie­ger and Frank­furt part­ner Dr. Jan Schu­bert, the team included London coun­sel Jakob Egle and asso­cia­tes Dr. Mattias Prange, Lena Pirner (both Frank­furt) and Romain Tourenne (London).
In Munich, part­ner Kai Gesing and asso­cia­tes Yannick Ober­acker and Chris­toph Jacob advi­sed on IP issues, and part­ner Dr. Mark Zimmer advi­sed on employ­ment law issues. Part­ner Attila Borsos (Brussels) and Asso­ciate Alana Tink­ler (London) advi­sed on anti­trust issues and aspects of foreign direct investment.

Gibson Dunn regu­larly advi­ses Biosynth and KKR.

About Gibson Dunn

Gibson, Dunn & Crut­cher LLP is one of the leading inter­na­tio­nal law firms and is ranked among the top law firms world­wide in indus­try surveys and by autho­ri­ta­tive publi­ca­ti­ons. With more than 1,800 lawy­ers in 20 offices, the firm has a global presence in all major econo­mic regi­ons. Gibson Dunn offices are loca­ted in Abu Dhabi, Brussels, Century City, Dallas, Denver, Dubai, Frank­furt, Hong Kong, Hous­ton, London, Los Ange­les, Munich, New York, Orange County, Palo Alto, Paris, Beijing, San Fran­cisco, Singa­pore and Washing­ton, D.C. For more infor­ma­tion, visit www.gibsondunn.com.